ANAB
HOLD / NEUTRALMeanRevComposite
56.80
Technical
22.00
Fundamental
68.40
Rank
—
Price
49.20
Hurst
0.31
As of
Oct 6, 2026
Daily
AnaptysBio, Inc.
HealthcareBiotechnologyAnaptysBio is a San Diego-based biotechnology firm that identifies and licenses antibody therapeutics to partner companies. The company holds rights to Jemperli, a PD-1 antagonist in development for solid tumors under a GSK partnership, and Quimilza, an IL-36 receptor antagonist being evaluated for generalized pustular psoriasis through two completed Phase 3 trials conducted with Vanda Pharmaceuticals.
Market cap
$1.4B
P/E (trailing)
—
P/E (forward)
10.47
PEG ratio
—
Dividend yield
0.00%
Beta
0.37
52w range
20.18 – 72.36
Return on equity
—
Profit margin
+246.96%
Revenue growth
+23.50%
Earnings growth
—
Price history
1Y: 47.51 (+98.0%) · range 22.06–69.81
Cycle position
40/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 34 · NOT READY · exit proximity 0
Conviction
36/ 100 · maturity 100%
VScore.4018
Buildup.2050
EMA entry setup.2534
Fundamentals.1568
Volume profile
POC
55.58
Price vs POC
-14.5%
Overhead supply
92%
Runway
+6.8%
Value area 48.32–60.15 · 92% of 120d volume overhead · heavy supply
Get an AI analyst's read on this ticker.Open the AI analyst
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Nov 4, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +5.90% | +10.77% | 13/20d |
| 40d | +5.90% | +10.77% | 13/40d |